Single-dose pharmacokinetics of daptomycin in pediatric patients 3-24 months of age

Pediatric Infectious Disease Journal

Volumn 33, Issue 9, 2014, Pages 936-939

  Bradley, John S ^a   Benziger, David ^b   Bokesch, Paula ^b   Jacobs, Richard ^c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b CUBIST PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

Author keywords

Daptomycin; Pediatric; Pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DAPTOMYCIN;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; CHILD; CLINICAL ARTICLE; CONSTIPATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; FEMALE; HEMATOGENOUS OSTEOMYELITIS; HUMAN; INFANT; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION; VOLUME OF DISTRIBUTION AT STEADY-STATE;

EID: 84964258042     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000318     Document Type: Article

References (13)

1. Kullar R, Davis SL, Kaye KS, et al. Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia. Pharmacotherapy. 2013;33:3-10.
2. Boucher H W, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1-12.
3. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010;23:616-687.
4. Baltz RH. Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Curr Opin Chem Biol. 2009;13:144-151.
5. ® (Daptomycin for Injection). Lexington, MA: Cubist Pharmaceuticals Inc; 2013.
6. Aswani R, Marti M G L. Use of daptomycin in neonates: a case report and review of the literature. J Pediatr Infect Dis. 2012;7:135-138.
7. Cohen-Wolkowiez M, Watt KM, Hornik C P, et al. Pharmacokinetics and tolerability of single-dose daptomycin in young infants. Pediatr Infect Dis J. 2012;31:935-937.
8. Abdel-Rahman SM, Benziger D P, Jacobs R F, et al. Single-dose pharmacokinetics of daptomycin in children with suspected or proved Gram-positive infections. Pediatr Infect Dis J. 2008;27:330-334.
9. Abdel-Rahman SM, Chandorkar G, Akins RL, et al. Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10 mg/kg in children aged 2 to 6 years with suspected or proved Gram-positive infections. Pediatr Infect Dis J. 2011;30:712-714.
10. Tally F P, Zeckel M, Wasilewski MM, et al. Daptomycin: a novel agent for Gram-positive infections. Expert Opin Investig Drugs. 1999;8:1223-1238.
11. Dvorchik BH, Brazier D, DeBruin MF, et al. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003;47:1318-1323.
12. Dvorchik B, Arbeit RD, Chung J, et al. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2004;48:2799-2807.
13. Oleson FB Jr, Berman CL, Kirkpatrick JB, et al. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother. 2000;44:2948-2953.